{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T16:10:07Z","timestamp":1745770207652,"version":"3.40.4"},"reference-count":4,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Ocular diseases are very common in many of the systemic diseases such as sarcoidosis, and may sometimes be the presenting symptom of the disease. In this case report, we present an unusual reaction of the sarcoid granuloma to carbonic anhydrase enzyme inhibitors (CAIs), which was encountered in a patient with ocular sarcoidosis. This observation was taken after a 2-week interval between a CT scan orbits and an MRI orbits which showed a decrease in size from 4\u00d73\u00d74\u2005cm to 2.5\u00d72.5\u00d72\u2005cm, respectively. We suspected the dorzolamide CAI to have had a significant role in the reduction in size. It is suggested that acidotic changes that occur due to the effect of the carbonic anhydrase inhibitor causes electrolyte imbalance, intracellular as well as extracellular, which lead to the reduction in the size of the granuloma.<\/jats:p>","DOI":"10.1136\/bcr-2013-200391","type":"journal-article","created":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T16:30:33Z","timestamp":1374856233000},"page":"bcr2013200391","source":"Crossref","is-referenced-by-count":1,"title":["Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor"],"prefix":"10.1136","volume":"2013","author":[{"given":"Yahya A H","family":"Khedr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulla H","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,7,26]]},"reference":[{"key":"2025042708542728000_2013.jul26_1.bcr2013200391.1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/bjo.84.1.110","article-title":"Ocular involvement in sarcoidosis","volume":"2013","author":"Rothova","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"2025042708542728000_2013.jul26_1.bcr2013200391.2","unstructured":"Hunter DG Foster CS . Ocular manifestations of sarcoidosis. In: Albert DM Jakobiec FA . eds Principles and practice of ophthalmology. Philadelphia: WB Saunders, 1994:443\u201350."},{"key":"2025042708542728000_2013.jul26_1.bcr2013200391.3","first-page":"336","article-title":"Systemic sarcoidosis with bilateral orbital involvement: MR findings","volume":"2013","author":"Simon","year":"1998","journal-title":"AJNR Am J Neuroradiol"},{"key":"2025042708542728000_2013.jul26_1.bcr2013200391.4","unstructured":"From FDA reports: Acetazolamide and Sarcoidosis, eHealthME. June 2013. http:\/\/www.ehealthme.com\/ds\/acetazolamide\/sarcoidosis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-200391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:54:35Z","timestamp":1745769275000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-200391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,26]]},"references-count":4,"alternative-id":["10.1136\/bcr-2013-200391"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-200391","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2013,7,26]]}}}